News | December 13, 2017

Principia Biopharma initiates clinical trial for PRN1008 in patients with Immune Thrombocytopenia Purpura Preclinical Data Presented at American Society of Hematology Annual Meeting Support ITP Indication  SOUTH SAN FRANCISCO, CALIF., December 13, 2017  Principia...

News | October 3, 2017

Ultragenyx Enters into Definitive Agreement to Acquire Dimension for $6.00 Per Share in Cash in a Transaction Valued at Approximately $151 Million Based on Currently Outstanding Shares Combined Company will be Strongly Positioned to Bring Needed New Therapies to...

News | November 15, 2017

Arvinas Expands Strategic License Agreement with Genentech Expansion of 2015 agreement brings total deal value to potentially exceed $650 million NEW HAVEN, Conn., November 15, 2017 – Arvinas LLC, a private biotechnology company creating a new class of drugs based on...

News | November 15, 2017

Jefferson Health Selects Kyruus’ Solutions to Support Its Expansion and Enhance Patient Access Growing Health System to Build Comprehensive Provider Directory and Optimize Patient-Provider Matching Boston, MA – Kyruus, a leader in provider search and scheduling...

News | November 09, 2017

SANOFI, PRINCIPIA AGREE TO DEVELOP MULTIPLE SCLEROSIS DRUG CANDIDATE Clinical-stage oral drug candidate (PRN2246) with the potential to treat multiple sclerosis Principia to receive $40 million upfront payment, future milestone payments could total $765 million...

News | October 9, 2017

Neuronetics Named 2017 Health Care Innovator by Philadelphia Business Journal Recognized for company’s breakthrough non-drug depression treatment, NeuroStar® Advanced Therapy Malvern, Pa., October 9, 2017 – Neuronetics, Inc., a privately held medical device company...